ACE Inhibitors, ARBs, and ARNIs Can Be Used with Lithium, But Require Intensive Monitoring
The combination of lithium with ACE inhibitors, ARBs, or ARNIs is not absolutely contraindicated, but requires careful consideration and close monitoring due to the significant risk of lithium toxicity. The FDA label explicitly warns about this interaction, and clinical evidence demonstrates that these combinations can substantially increase lithium levels 1.
Understanding the Drug Interaction
The mechanism is straightforward: ACE inhibitors and ARBs reduce sodium reabsorption in the renal tubules, which decreases lithium clearance and can elevate serum lithium concentrations by 25-40% 1, 2. This creates a real risk of lithium toxicity, which can manifest as diarrhea, vomiting, tremor, ataxia, drowsiness, or muscular weakness 1.
When This Combination Might Be Necessary
Despite the interaction risk, there are clinical scenarios where renin-angiotensin system (RAS) blockade becomes medically necessary in patients on chronic lithium:
- Hypertension with diabetes and albuminuria - where ACEi/ARB are first-line agents 3, 4
- Heart failure with reduced ejection fraction - where ARNI or ACEi/ARB reduce mortality 5
- Chronic kidney disease with proteinuria - where ACEi/ARB slow progression 3
- Post-myocardial infarction - where these agents improve outcomes 6
Clinical Decision Algorithm
Step 1: Assess if RAS blockade is truly necessary
- Is there a compelling indication (HFrEF, diabetic nephropathy, post-MI)?
- Have alternative antihypertensives been considered (calcium channel blockers, thiazides)?
- For simple hypertension without compelling indications, prefer calcium channel blockers or thiazide diuretics 7, 8, 9, 10
Step 2: If RAS blockade is required, implement strict safety protocols
Before initiation:
- Ensure adequate hydration status (2500-3000 mL daily fluid intake) 1
- Absolutely avoid concurrent thiazide diuretics - this combination dramatically increases toxicity risk 11, 12
- Check baseline lithium level, creatinine, and electrolytes
- Verify patient maintains normal salt intake 1
Step 3: Monitoring protocol
- Check lithium levels within 1 week of starting ACEi/ARB/ARNI
- Recheck at 2-4 weeks, then monthly for 3 months 3, 4
- Monitor creatinine and potassium simultaneously 3, 4
- Anticipate needing to reduce lithium dose by 25-35% 2
- Continue monitoring every 3 months once stable
Step 4: Patient education
- Maintain consistent fluid intake (2500-3000 mL/day) 1
- Maintain normal dietary sodium 1
- Immediately report symptoms of lithium toxicity 1
- Avoid NSAIDs, which compound the interaction 1, 12
Critical Caveats
The combination becomes particularly hazardous in:
- Elderly patients (>65 years) - who show greater susceptibility to lithium accumulation 2
- Patients with baseline renal impairment (CrCl <60 mL/min) 2
- Volume-depleted states (diarrhea, vomiting, excessive sweating) 1
- Concurrent thiazide diuretic use - this is the most dangerous scenario 11, 12
Evidence Quality and Nuances
The FDA drug label provides the strongest warning, stating lithium "should generally not be given" with conditions that impair renal clearance, and specifically cautions about ACE inhibitors reducing lithium clearance 1. However, real-world case series demonstrate that with meticulous monitoring and avoidance of thiazides, the combination can be managed 11.
A retrospective study of 20 patients showed lithium concentrations increased 36% and clearance decreased 25% after ACE inhibitor initiation, with 4 patients developing toxicity symptoms 2. Importantly, 25-35% of the clearance change correlated with changes in serum creatinine and patient age 2.
The key insight from clinical experience: dehydration and thiazide co-administration appear to be necessary cofactors for severe toxicity, rather than ACE inhibitors alone 11.
Practical Bottom Line
If RAS blockade is medically necessary in a lithium patient:
- Choose the indication carefully - ensure it's truly compelling
- Never combine with thiazide diuretics
- Ensure excellent hydration
- Plan for lithium dose reduction (typically 25-35%)
- Monitor lithium levels weekly initially, then monthly
- Consider psychiatric consultation for lithium management
If hypertension is the only indication and there are no compelling reasons for RAS blockade, choose calcium channel blockers or non-thiazide diuretics instead 9, 10. This avoids the interaction entirely while still achieving blood pressure control.